Home Stock

Stock Research: Cresco Labs

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Cresco Labs

CNX:CL CA22587M1068
29
  • Value
    41
  • Growth
    22
  • Safety
    Safety
    58
  • Combined
    25
  • Sentiment
    57
  • 360° View
    360° View
    29
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Cresco Labs Inc. is an integrated multi-state cannabis operator in the United States. The Company is licensed to cultivate, manufacture, and sell retail and medical cannabis products primarily through Sunnyside, Cresco Labs’ national dispensary brand, and third-party retail stores. Its family brands include Cresco, High Supply, Good News, Wonder Wellness Co., FloraCal Farms, Remedi and Mindy’s. Its portfolio consists of over 500 products. Its products are sold in over 1,400 dispensaries across the country. Cresco offers flower, liquid live resin vapes and concentrates available in a variety of product forms at dispensaries and retail locations. Its High Supply is lab-tested, and available in vape carts, vape pens, flowers, popcorn, shakes, shorties, and concentrates. Its Remedi products provide a consistent and trusted alternative to traditional pharmaceuticals like opioids. Mindy’s offers dosed edibles created by James Beard. It is the wholesaler of branded cannabis products.

more

ANALYSIS: With an Obermatt 360° View of 29 (better than 29% compared with alternatives), overall professional sentiment and financial characteristics for the stock Cresco Labs are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Cresco Labs. The consolidated Sentiment Rank has a good rank of 57, which means that professional investors are more optimistic about the stock than for 57% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 58 or better than 58% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 41, meaning that the share price of Cresco Labs is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 22. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Refinancing
Country USA
Industry Pharmaceuticals
Size Medium
Website crescolabs.com
Index
Sound Pay USA
Cresco Labs stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
41 32 74 35
Growth
22 11 3 3
Safety
Safety
58 13 20 22
Sentiment
57 22 34 70
360° View
360° View
29 1 7 10
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
75 28 46 61
Opinions Change
50 50 36 50
Pro Holdings
n/a 26 42 24
Market Pulse
47 55 58 82
Sentiment
57 22 34 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
41 32 74 35
Growth
22 11 3 3
Safety Safety
58 13 20 22
Combined
25 1 7 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
90 26 86 68
Price vs. Earnings (P/E)
67 1 65 25
Price vs. Book (P/B)
17 63 65 40
Dividend Yield
1 1 1 1
Value
41 32 74 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
34 15 14 71
Profit Growth
19 80 42 8
Capital Growth
56 11 19 12
Stock Returns
41 15 29 29
Growth
22 11 3 3
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
19 20 24 50
Refinancing
91 12 17 7
Liquidity
57 45 57 46
Safety Safety
58 13 20 22

Similar Stocks

Discover high‑ranked alternatives to Cresco Labs and broaden your portfolio horizons.

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Global Payments

NYQ:GPN
Country: USA
Industry: Other Financial Services
Size: X-Large
Full Stock Analysis

Merck (USA)

NYQ:MRK
Country: USA
Industry: Pharmaceuticals
Size: XX-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews